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 Dear Editor,
In 2011, the fluoxetine for motor recovery after acute ischemic 
stroke (FLAME) trial described a significant improvement in motor 
deficits among patients who were prescribed fluoxetine while 
recovering from an ischemic stroke1. Following the publication of 
FLAME and similar trials2,3, there is growing evidence that providers 
should consider prescribing a selective serotonin reuptake inhibitor 
for a patient who has experienced a stroke4. However, the psychiatric 
consequences or diagnostic contraindications of this therapy have 
not been discussed.
We examined the effects of initiating fluoxetine in a patient 
with bipolar 2 disorder following left posterior inferior cerebellar 
artery ischemic stroke. The patient’s medical and psychiatric history, 
physical and neurological examinations, pertinent family history, 
social history, and laboratory data were used in our assessment and 
subsequent treatment of their condition. The patient’s anonymity was 
maintained by withholding identifying information.
The patient was hospitalized for treatment of left posterior 
inferior cerebellar artery ischemic stroke roughly two weeks after 
stopping their home medications consisting of insulin, metoprolol, 
and lithium. While recovering from their stroke, the patient resumed 
taking metoprolol and insulin though refused lithium or another 
mood stabilizer. To treat residual symptoms of their ischemic stroke, 
fluoxetine 40 mg by mouth daily was initiated without a concurrent 
mood stabilizer. Soon thereafter, the patient developed symptoms 
concerning for hypomania: increased rate of speech, irritability, 
psychomotor agitation, tangential thought process, and reduced 
need for sleep. The patient’s urine toxicology was negative for drugs 
of abuse, and aside from fluoxetine the patient had not been treated 
with medications associated with drug-induced mania. Though the 
patient refused medication to treat symptoms of hypomania, they 
agreed to discontinue fluoxetine. Over the course of multiple days, 
the patient’s symptoms improved, and the patient did not require 
inpatient psychiatric treatment for acute stabilization.
We report that initiation of fluoxetine for motor recovery after 
ischemic stroke carries the risk of inducing hypomania in a patient 
with bipolar 2 disorder who is not taking a mood stabilizer. Fluoxetine 
is one of many medications that can induce symptoms of mania5. The 
risk of triggering medication-induced mania is heightened among 
patients with bipolar disorder6-8. Among patients with known bipolar 
disorder, treatment with an effective mood stabilizer or atypical 
antipsychotic is necessary prior to starting an antidepressant to 
mitigate the risk of triggering mania9,10. Providers should understand 
the benefits of conducting a psychiatric review of systems and 
appreciate the risks of prescribing fluoxetine following an ischemic 
stroke to patients with a history of bipolar disorder.
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